We target diseases in premature infants or caused by antibiotic-resistant bacteria

Latest press releases

2026-02-06 07:30 Infant Bacterial Therapeutics AB (publ) Year-end-report January 1 – December 31, 2025 Regulatory
2025-12-11 18:05 Infant Bacterial Therapeutics secures partnership with BioConnection for production of Drug Product
2025-11-25 18:41 IBT changes the IBP-9414 pathway for approval following discussions with the FDA Regulatory MAR
2025-11-20 16:42 Infant Bacterial Therapeutics AB secures partnership with Recipharm Advanced Bio for production of drug substance

Subscribe to our press releases

Research and Development

IBT is a pharmaceutical company whose purpose is to develop and market medicines for diseases affecting premature infants.
IBT's main focus is the drug candidate IBP-9414, a formulated bacterial strain naturally found in breast milk. IBP-9414 is expected to be the first product in the new class of biological medicines called "Live Biotherapeutic Products" for premature infants. The development of IBP-9414 is currently in its final phase. The portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122.
Read More

Calendar

FEBRUARY 6, 2026
Year-end report 2025
MARCH 27, 2026
Annual report 2025
MAY 6, 2026
Interim report Q1 January – March 2026
MAY 7, 2026
Annual General Meeting 2026
AUGUST 26, 2026
Interim report Q2 April – June 2026
NOVEMBER 13, 2026
Interim report Q3 July – September 2026
Read More